• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by GE HealthCare Technologies Inc.

    9/22/25 4:44:03 PM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001889865
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    GE HealthCare Technologies Inc.
    SEC File Number
    001-41528
    Address of Issuer
    500 W. Monroe Street
    Chicago
    ILLINOIS
    60661
    Phone
    8337351139
    Name of Person for Whose Account the Securities are To Be Sold
    Kenneth Stacherski
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Former Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Shares
    UBS Financial Services Inc
    1000 Harbor Blvd
    3rd Floor
    Weehawken � NJ � 07086
    19524145377345656203709/22/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/01/2024Restricted Stock VestGE HealthCare Technologies Inc.Checkbox not checked118509/22/2025NA
    Common11/01/2024Restricted Stock VestGE HealthCare Technologies Inc.Checkbox not checked1513709/22/2025NA
    Common02/01/2025Restricted Stock VestGE HealthCare Technologies Inc.Checkbox not checked89509/22/2025NA
    Common09/01/2025Restricted Stock VestGE HealthCare Technologies Inc.Checkbox not checked230709/22/2025NA

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Kenneth Stacherski
    500 W. Monroe Street
    Chicago � IL � 60661
    Common Shares09/12/202511757905590

    144: Remarks and Signature

    Remarks
    Date of Notice
    09/22/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/JOSEPH CASSIDY, for UBS Financial Services Inc, as attorney-in-fact for Kenneth Stacherski

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $GEHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    9/9/2024$90.00Neutral
    JP Morgan
    8/6/2024$100.00Buy
    Stifel
    5/30/2024$87.00Neutral
    Goldman
    More analyst ratings

    $GEHC
    SEC Filings

    View All

    SEC Form 144 filed by GE HealthCare Technologies Inc.

    144 - GE HealthCare Technologies Inc. (0001932393) (Subject)

    9/22/25 4:44:03 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form 144 filed by GE HealthCare Technologies Inc.

    144 - GE HealthCare Technologies Inc. (0001932393) (Subject)

    9/12/25 4:47:37 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SCHEDULE 13G filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G - GE HealthCare Technologies Inc. (0001932393) (Subject)

    8/13/25 4:35:15 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GE HealthCare upgraded by UBS with a new price target

    UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

    5/5/25 8:34:55 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare upgraded by Goldman with a new price target

    Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

    3/11/25 7:35:30 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare upgraded by Jefferies with a new price target

    Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

    1/8/25 7:50:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare debuts AI-supported solution, designed to improve and shorten the radiation therapy workflow, at ASTRO 2025

    Early adopters of Intelligent Radiation Therapy (iRT) to date have reduced simulation to treatment planning time from seven days to seven minutes1 via integration with RayStation® by RaySearch Laboratories The new version of iRT enhances connectivity, uses insights to improve efficiency, and includes a solution to manage workflows for the emerging field of theranostics GE HealthCare will spotlight its comprehensive radiation oncology portfolio at its booth, underscoring the company's commitment to accelerating global access to radiation therapy GE HealthCare (NASDAQ: GEHC) today announced updates to Intelligent Radiation Therapy (iRT), a new version of the company's software solut

    9/25/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare announces cash dividend for third quarter of 2025

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the third quarter of 2025 payable on November 14, 2025 to all shareholders of record as of October 24, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for

    9/24/25 3:58:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

    BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.  (NASDAQ:LNTH) and GE HealthCare (NASDAQ:GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus' piflufolastat F18 (PYLARIFY® in U.S. market) in Japan for prostate cancer diagnostics and companion diagnostic use. PYLARIFY is used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The agreement includes the transfer of regulatory dossiers, manufacturing competencies and technical support to enable GE HealthCare to drive clinical development

    9/24/25 1:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Imaging Rott Roland covered exercise/tax liability with 4,620 shares and exercised 5,341 shares at a strike of $55.91, increasing direct ownership by 3% to 29,122 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/12/25 4:05:10 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Chief Enterprise Oper. Officer Stacherski Kenneth R. covered exercise/tax liability with 892 shares, decreasing direct ownership by 2% to 40,996 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:19:36 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Chief People Officer Holton Adam Y covered exercise/tax liability with 464 shares, decreasing direct ownership by 3% to 16,768 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:18:39 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/2/24 6:00:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    View All

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

    GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

    4/9/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare's MIM Software collaborates with Elekta to help enhance radiation therapy treatments and improve patient outcomes

    Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

    4/22/24 7:07:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    10/22/24 4:16:16 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    4/2/24 4:07:29 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Financials

    Live finance-specific insights

    View All

    GE HealthCare announces cash dividend for third quarter of 2025

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the third quarter of 2025 payable on November 14, 2025 to all shareholders of record as of October 24, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for

    9/24/25 3:58:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare reports second quarter 2025 financial results

    Revenue growth was 3% year-over-year; Organic revenue growth* was 2% Net income margin was 9.7% versus 8.9% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 14.6% versus 15.3% Diluted earnings per share (EPS) were $1.06 versus $0.93 for the prior year; Adjusted EPS* was $1.06 versus $1.00 Cash flow from operating activities was $94 million versus $(119) million for the prior year; Free cash flow* was $7 million versus $(182) million Raises full-year 2025 guidance GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2025. GE HealthCare President and CEO Peter Arduini said, "We were pleas

    7/30/25 6:20:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare to announce second quarter 2025 results on July 30, 2025

    GE HealthCare (NASDAQ:GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno

    7/7/25 8:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care